K. Kluck

发表

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma

S. Fröhling, M. Kriegsmann, P. Schirmacher, 2021, Cancer Immunology, Immunotherapy.

Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.

A. Stenzinger, J. Budczies, F. Sinicrope, 2020, Cancer discovery.

Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)

S. Fröhling, D. Kazdal, J. Budczies, 2022, npj Precision Oncology.

The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.

D. Kazdal, J. Budczies, M. Kirchner, 2022, European journal of cancer.

Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types

D. Kazdal, J. Budczies, T. Seufferlein, 2022, The journal of pathology. Clinical research.

A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma

S. Fröhling, M. Kriegsmann, P. Schirmacher, 2021, Oncoimmunology.

Decoding and targeting the molecular basis of MACC1-driven metastatic spread: lessons from big data mining and clinical-experimental approaches.

J. Budczies, W. Walther, U. Stein, 2020, Seminars in cancer biology.

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma

S. Fröhling, M. Kriegsmann, P. Schirmacher, 2021, ESMO open.

Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis

D. Kazdal, J. Budczies, T. Stiewe, 2023, Cell death discovery.

The different immune profiles of normal colonic mucosa in cancer-free Lynch syndrome carriers and Lynch syndrome colorectal cancer patients.

M. Kloor, M. von Knebel Doeberitz, D. Bishop, 2021, Gastroenterology.

Analysis of rare fusions in NSCLC: genomic architecture and clinical implications

D. Kazdal, J. Budczies, F. Herth, 2023, Lung Cancer.

Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas.

D. Kazdal, J. Budczies, F. Herth, 2023, Lung cancer.

Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD)

S. Fröhling, D. Kazdal, J. Budczies, 2023, Translational oncology.

Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients

J. Budczies, M. Boerries, S. Lassmann, 2023, NPJ precision oncology.

Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

T. Hielscher, K. Kluck, L. Weiss, 2023, Nature communications.

Tumour mutational burden: clinical utility, challenges and emerging improvements.

P. Christopoulos, M. Allgäuer, K. Kluck, 2024, Nature reviews. Clinical oncology.